News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
597,223 Results
Type
Article (46180)
Company Profile (218)
Press Release (550825)
Section
Business (172134)
Career Advice (2515)
Deals (31779)
Drug Delivery (117)
Drug Development (75954)
Employer Resources (156)
FDA (16123)
Job Trends (13230)
News (304485)
Policy (31762)
Tag
Academia (2353)
Alliances (43117)
Alzheimer's disease (1333)
Approvals (16057)
Artificial intelligence (148)
Bankruptcy (313)
Best Places to Work (9876)
Biotechnology (115)
Breast cancer (185)
Cancer (1360)
Cardiovascular disease (112)
Career advice (2103)
Cell therapy (287)
Clinical research (60786)
Collaboration (455)
Compensation (266)
COVID-19 (2604)
C-suite (108)
Data (1317)
Diabetes (181)
Diagnostics (5385)
Drug pricing (106)
Earnings (67355)
Employer resources (142)
Events (89672)
Executive appointments (376)
FDA (16811)
Funding (375)
Gene therapy (207)
GLP-1 (690)
Government (3887)
Healthcare (15383)
Infectious disease (2700)
Inflammatory bowel disease (110)
Interviews (460)
IPO (14923)
Job creations (3754)
Job search strategy (1763)
Layoffs (463)
Legal (7659)
Lung cancer (205)
Lymphoma (102)
Manufacturing (219)
Medical device (11313)
Medtech (11317)
Mergers & acquisitions (17026)
Metabolic disorders (519)
Neuroscience (1667)
NextGen Class of 2024 (5262)
Non-profit (3313)
Northern California (1612)
Obesity (302)
Opinion (217)
Patents (124)
People (50319)
Phase I (18224)
Phase II (26459)
Phase III (21015)
Pipeline (521)
Postmarket research (2548)
Preclinical (7541)
Radiopharmaceuticals (221)
Rare diseases (273)
Real estate (5192)
Regulatory (21746)
Research institute (2180)
Resumes & cover letters (416)
Southern California (1368)
Startups (3231)
United States (14106)
Vaccines (640)
Weight loss (237)
Date
Today (120)
Last 7 days (572)
Last 30 days (2317)
Last 365 days (33334)
2024 (33194)
2023 (37222)
2022 (47704)
2021 (51385)
2020 (48652)
2019 (39202)
2018 (29904)
2017 (30548)
2016 (29175)
2015 (32677)
2014 (26562)
2013 (22192)
2012 (23752)
2011 (24429)
2010 (22346)
Location
Africa (757)
Arizona (155)
Asia (36805)
Australia (6017)
California (3570)
Canada (1246)
China (275)
Colorado (166)
Connecticut (190)
Europe (83924)
Florida (513)
Georgia (119)
Illinois (335)
Indiana (191)
Maryland (610)
Massachusetts (2814)
Michigan (142)
Minnesota (241)
New Jersey (1057)
New York (991)
North Carolina (731)
Northern California (1612)
Ohio (120)
Pennsylvania (846)
South America (1132)
Southern California (1368)
Texas (513)
Washington State (374)
597,223 Results for "veloxis pharmaceuticals a s".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Bio NC
Veloxis Pharmaceuticals Selected to Present at the 2024 American Transplant Congress in Philadelphia
Veloxis Pharmaceuticals, Inc. is pleased to announce the presentation of VEL-101 research at the 2024 American Transplant Congress (ATC).
May 30, 2024
·
5 min read
FDA Tracker
2024 Ends With Lilly’s Landmark GLP-1 Sleep Apnea Approval
Other notable greenlights this year include Bristol Myers Squibb’s Cobenfy, the first novel therapeutic for schizophrenia in 35 years, and Madrigal Pharmaceuticals’ Rezdiffra, the first-ever treatment for MASH.
December 24, 2024
·
223 min read
·
BioSpace Editorial Staff
Bio NC
Lyfebulb and Veloxis Pharmaceuticals Announce Finalists for 2022 Innovation Challenge in Organ Transplantation
Lyfebulb, a patient-empowerment platform that connects patients with industry experts to support user-driven innovation, and Veloxis Pharmaceuticals, a fully integrated specialty pharmaceutical company, are pleased to announce 10 finalists for the 2022 “Transforming Organ Transplantation Through Innovation” Challenge.
September 19, 2022
·
4 min read
Press Releases
U.S. Pharmaceutical CDMO Market to Reach USD 83.86 Billion to 2034
December 23, 2024
·
1 min read
Bio NC
Biohope and C. Alan Foundation Named Winners of the 2022 Lyfebulb-Veloxis Innovation Challenge: Transforming Organ Transplantation
Lyfebulb and Veloxis Pharmaceuticals are excited to announce that Biohope was selected as the winner of the Innovation Award and C. Alan Foundation as the winner of the Impact Award at the 2022 Lyfebulb-Veloxis Innovation Challenge: Transforming Organ Transplantation.
October 17, 2022
·
4 min read
Bio NC
Lyfebulb and Veloxis Pharmaceuticals Seek Applicants for the Global 2022 Innovation Challenge in Organ Transplantation
Lyfebulb, a patient-empowerment platform that connects patients with industry experts to support user-driven innovation, and Veloxis Pharmaceuticals, an Asahi Kasei, fully integrated specialty pharmaceutical company, invite entrepreneurs to apply to their “Transforming Organ Transplantation Through Innovation” Challenge.
July 26, 2022
·
4 min read
Podcast
BridgeBio’s ATTR-CM Approval, Cassava’s Alzheimer’s Failure, Trump’s Cabinet Picks, More
BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for Amvuttra in the indication; Cassava’s controversial Alzheimer’s drug flunks Phase III; Amgen’s MariTide fails to impress investors, Donald Trump’s controversial nominations continue.
November 27, 2024
·
1 min read
·
Heather McKenzie
Press Releases
Baxter Announces Continued Growth of Pharmaceuticals Portfolio With Five Injectable Product Launches in the U.S.
December 11, 2024
·
19 min read
Press Releases
Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension)
November 25, 2024
·
4 min read
Press Releases
KRTL Holding Announces KRTL Biotech Facilitates FDA Registration of SIGMACORP as a U.S. Pharmaceutical Manufacturer
December 6, 2024
·
4 min read
1 of 59,723
Next
